Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Clinical Trial ID NCT02215967

PubWeight™ 11.89^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02215967

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.	Blood	2011	8.26
2	Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.	Nat Rev Clin Oncol	2013	1.91
3	T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.	Blood	2016	1.72
4	B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.	Clin Cancer Res	2013	1.60
5	Engineered T cells: the promise and challenges of cancer immunotherapy.	Nat Rev Cancer	2016	1.51
6	Driving CAR T-cells forward.	Nat Rev Clin Oncol	2016	1.09
7	Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.	Clin Cancer Res	2016	0.95
8	Promising therapies in multiple myeloma.	Blood	2015	0.89
9	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.	Bone Marrow Transplant	2015	0.89
10	Targeting B-cell maturation antigen in multiple myeloma.	Immunotherapy	2015	0.84
11	Trial Watch: Adoptive cell transfer for oncological indications.	Oncoimmunology	2015	0.84
12	Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.	Bone Marrow Transplant	2016	0.82
13	Development of Novel Immunotherapies for Multiple Myeloma.	Int J Mol Sci	2016	0.82
14	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.	Cancer J	2016	0.76
15	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?	Onco Targets Ther	2016	0.76
16	Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.	J Mol Med (Berl)	2015	0.75